CERT1 and metabolic syndrome: In fact, in the present study, while no one in the NW group was categorized as an individual at increased or high risk, proportions of OB-MetS− and OB-MetS+ subjects were included in the categories at low and moderate risk, suggesting that CERT1, rather than the diagnosis of metabolic syndrome, might better identify the obese subjects that need more frequent medical supervision and, importantly, a more aggressive lifestyle change and pharmacological therapy, aimed at reducing the individual CVD risk [6].